LNTH · Lantheus Holdings, Inc.
$100.29
-0.10% last session
End-of-day data · close of 2026-09-11
Market cap
$7B
Enterprise value
$7B
Trailing P/E
24.0
Forward P/E
15.7
Dividend yield
—
Beta
-0.03
Avg volume
1M
Employees
1K
Daily Change %
-0.10%
5 Days Change
-0.27%
10 Days Change
-0.26%
30 Days Change
0.02%
60 Days Change
-4.68%
Month to Day Change
-0.18%
Year to Day Change
51.31%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LNTH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-04
Latest call per bank · past 12 months
Goldman Sachs
Neutral$77.00
-23.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-04 | Truist Securities | Downgrade | Buy → Hold | $125 → $103 |
| 2026-08-04 | CJS Securities | Downgrade | Market Outperform → Market Perform | $0.00 |
| 2026-08-03 | William Blair | Downgrade | Outperform → Market Perform | $0.00 |
| 2026-08-03 | TD Cowen | Downgrade | Buy → Hold | $110 → $103 |
| 2026-07-29 | Mizuho | Maintains | Outperform | $120 → $115 |
| 2026-07-16 | Truist Securities | Maintains | Buy | $115 → $125 |
| 2026-07-15 | Mizuho | Maintains | Outperform | $115 → $120 |
| 2026-07-09 | B. Riley Securities | Maintains | Buy | $97.00 → $129 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 44 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.0% below the 50-day MA ($102.36).
- Price vs 200-day MA: Trading 17.8% above the 200-day MA ($85.15).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.07) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($50.11) and high ($110.94).
LNTH Price Chart
Loading chart for LNTH…
Fundamentals
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$58B 16.8% YTD
TEVA
Teva Pharmaceutical Industries
$42B 18.1% YTD
HLN
Haleon plc
$41B -6.9% YTD
ZTS
Zoetis Inc.
$30B -40.8% YTD
UTHR
United Therapeutics Corporation
$22B 4.0% YTD
VTRS
Viatris Inc.
$19B 35.6% YTD
NBIX
Neurocrine Biosciences, Inc.
$16B 9.4% YTD
ELAN
Elanco Animal Health Incorporat
$11B 4.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.